Re: Farmas USA
NVIV
Sixth Patient Conversion in The INSPIRE Study of the Neuro-Spinal Scaffold™
the patient enrolled in December in the INSPIRE study of the Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury in the time between discharge and the one-month evaluation. This is the sixth out of the eleven patients (54.5% conversion rate) in follow-up to have had an AIS grade improvement. Two patients who have not yet converted are early in follow-up, with conversion possible before the six-month endpoint.
Intento entrar a largo mientras aún no se ha activado el pre.
Edito: No creo que me entre. Y preparo corto para después.
Re: Farmas USA
CASC
offerings of 23,182,000 shares of its common stock at a price to the public of $3.30 per share, for expected gross proceeds of approximately $76.5 million and 1,818 shares of its Series E convertible preferred stock at a price to the public of $3,300 per share, for expected gross proceeds of approximately $6.0 million.
http://finance.yahoo.com/news/cascadian-therapeutics-prices-82-5-135046454.html
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
Off-topic
Son unos chorizos..yo estoy en discusiones con ellos por el cambio euro/dolar y los tíos que no reconocen que aplican un % sobre el cambio diario cuando dí la orden a cierre de mercado a 1,055 y me hacen el cambio a 1,08X..que si el par, que si el no par...el par los &%(%&/%(%&
Me parece bien que me cobren la comisión pero que me lo digan y no me mientan a la cara.
Bankinter
Re: Farmas USA
Re: Farmas USA
Tenia tenía guardado el post, así que lo he encontrado rápido...
http://seekingalpha.com/article/3996739-gilead-temporarily-dead-money-investment-case-dead
GILD